Prostate Cancer
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (CA071-1000)
- Details
ClinicalTrials.gov ID:
NCT06764485
Diagnosis Type:
NA
USOR Number:
- Address
,
P: